Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Home infusion therapy refers to the process in which patient receive medication via needle or intravenous sets into the vein. It allows for the delivery of certain drugs like anti-infective, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, and endocrinology with using home infusion therapy products at patient‘s home. Besides, the home infusion therapy helps to keep high risk patient with serious infection out of hospital setting allowing them to receive treatment at home. In Asia Pacific, the home infusion therapy is expected to witness the growth at rapid pace during the forecast period owing to increasing preference for home infusion therapy, growing geriatric population, and demand for various home infusion therapy has propelled the market growth in Asia Pacific region.
Asia Pacific home infusion therapy is driven by different factor like growing geriatric population across the region has fuelled the growing demand for market. The geriatric population associated with chronic diseases often have increasing requirement for home infusion therapy specifically for long term care which has increased the market products demand in region. Besides, advancements in technology and rising prevalence of chronic disease is expected to fuel the market growth to huge extend. The increasing cases of cancer, cardiovascular diseases and rapid lifestyle changes leading to diabetes in different countries of Asia Pacific has fuelled the growth of market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Asia Pacific home infusion therapy market. In addition, complete analysis of changes on Asia Pacific home infusion therapy market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The Asia Pacific home infusion therapy market has positive growth due to COVID-19 as number of patient were having their chronic diseases therapies at homes which has ultimately boosted the growth of market.
The home infusion therapy market comprises of different market segment like product, application and country.
The Asia Pacific home infusion therapy market has different product including infusion pump, intravenous sets, IV cannulas, and needleless connectors. The infusion pump further includes sub segment like syringe infusion pump, ambulatory infusion pump, implantable infusion pump, insulin infusion pump and others. The infusion pump dominated the Asia Pacific home infusion therapy market during the estimated time period. The factor contributing market growth are it provide more flexibility to patient lifestyle while controlling the disease of patient. Likewise, the infusion medical device helps in delivering fluids into patient body according to requirement. In sub-segment of infusion pump, the syringe infusion pump followed by ambulatory infusion pump are likely to have emerging demand for market. The syringe pump helps to deliver small amount of drugs and fluid to patient. The different features of sub-segment is expected to drive the demand for market during the estimated time period. Also, needleless connectors is expected to experienced rapid growth during the estimated time period.
The Asia Pacific home infusion therapy market finds its major application in anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition and others. The anti-infective is expected to gain major market for home infusion therapy as the anti-infective are mostly for infusion of antibiotic, antiviral or antifungal drugs which is used to treat infection that do not respond to oral medicine. It provides a safe in home administration of anti-infective therapy with benefit for patient requiring long term anti-effective therapy. Likewise, chemotherapy is anticipated to have rapid growth during the forecast period owing burden of cancer patient in region and requirement for chemotherapy has fuelled the growth of market in Asia Pacific region.
Asia Pacific home infusion therapy market is studied for the following countries like China, India, Japan and Rest of APAC among others. China is anticipated to gain major market for home infusion therapy market owing to growing prevalence of chronic diseases across the population has led the demand for market. Besides, rising geriatric population having increasing requirement for home infusion therapy market is fuelling the market to huge extend. Furthermore, rising awareness for home infusion and adoption of market products is boosting the demand for market. Similarly, India is expected to hold second position in the market during the forecast period. The increasing incidence of cancer, diabetes, and cardiovascular diseases has fuelled the growth of market. Also, awareness for home infusion therapy market is accelerating the demand for market.
The key players in home infusion therapy market are B. Braun Melsungen AG, Becton, Dickinson and Company (BD) , NewIV , ICU Medical Inc, Plenum Tech Pvt Ltd, Baxter International Inc, JMS Co. Ltd, Silverline Meditech Pvt Ltd, Eli Lilly and Company , Fresenius Kabi, Terumo Corporation and AKAS Medical among others
April 2021: Medtronic had unveiled its extended infusion set, the first set that can be worn to deliver insulin for up to seven days in selected European countries. Infusion sets are tubing that provides insulin to the body form a pump and then usually need to be changed every few days. The extended infusion set doubles the times a set can be worn, it allows user to safely stay on insulin pump therapy with fewer interruption and insertion while providing improved convince for diabetes management routines.
April 2020: B.Braun Medical Inc had announced the US Food and Drug administration issued Emergency use authorization of B. Braun’s perfusor space syringe infusion pump, infusomat space volumetric infusion pump and outlook ES pump system for use in the tracheal delivery of continuous nebulized medication into nebulizer to treat patient of all ages with or suspended of having Coronavirus diseases.
The report analyses the Asia Pacific home infusion therapy market based on by product, application and country. The Asia Pacific home infusion therapy market has different product including infusion pump, intravenous sets, IV cannulas, and needleless connectors. The infusion pump further includes sub segment like syringe infusion pump, ambulatory infusion pump, implantable infusion pump, insulin infusion pump and others. The infusion pump dominated the Asia Pacific home infusion therapy market during the estimated time period. The Asia Pacific home infusion therapy market finds its major application in anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition and others. The anti-infective is expected to gain major market for home infusion therapy. Asia Pacific home infusion therapy market is studied for the following countries like China, India, Japan and Rest of APAC among others.
Why to buy this report:
